Abstract Number: 0244 • ACR Convergence 2022
Identification of Novel Response Predictors via Cardiovascular Biomarker Proteomic Analysis of Serum Samples from Patients with Early, Seropositive RA Treated with Abatacept or Adalimumab
Background/Purpose: Effective RA therapies should not only improve joint signs and symptoms, but also mitigate additional disease-related consequences, such as the increased risk of cardiovascular…Abstract Number: 0260 • ACR Convergence 2022
Impacts of Poor Prognostic Factors in Rheumatoid Arthritis on Clinical Outcomes and Treatment Choices from an Observational Cohort of Korean Patients with Rheumatoid Arthritis
Background/Purpose: The primary target for the treatment of rheumatoid arthritis (RA) is achieving remission or low disease activity with proper use of DMARD. Besides controlling…Abstract Number: 0277 • ACR Convergence 2022
Malignancy Events in the Filgotinib Rheumatoid Arthritis and Ulcerative Colitis Clinical Development Programs
Background/Purpose: Filgotinib (FIL) is a preferential oral Janus kinase (JAK) 1 inhibitor, approved for the treatment of RA and ulcerative colitis (UC) in Europe, the…Abstract Number: 0294 • ACR Convergence 2022
Safety and Efficacy of Upadacitinib in Patients with Rheumatoid Arthritis and Inadequate Response or Intolerance to Biologic DMARDs: Results Through 5 Years from the SELECT-BEYOND Study
Background/Purpose: To evaluate the long-term efficacy and safety of upadacitinib (UPA) over 5 yrs among patients with rheumatoid arthritis (RA) in a long-term extension (LTE)…Abstract Number: 0312 • ACR Convergence 2022
Dose-dependent Suppression of T Cell-Dependent Antibody Response in Healthy Volunteers by KPL-404, an Anti-CD40 Monoclonal Antibody, Supports Phase 2 Study in Patients with Rheumatoid Arthritis
Background/Purpose: An unmet need remains in patients with failure and/or inadequate response (IR) to biological disease-modifying antirheumatic drugs (bDMARD-IR) and/or Janus kinase inhibitors (JAKi-IR). The…Abstract Number: 0534 • ACR Convergence 2022
Synovial Transcriptomic Profiles Correlate with Disease Activity in Early Untreated Rheumatoid Arthritis
Background/Purpose: Synovitis is the common feature across all individuals with a diagnosis of rheumatoid arthritis (RA). Yet, cellular and transcriptomic alterations occuring in RA synovium…Abstract Number: 0592 • ACR Convergence 2022
Autoantibodies Targeting Malondialdehyde-modifications Are Potential Mediators of Inflammation and Bone Loss in RA, Acting via Macrophage and Osteoclast Regulatory Pathways
Background/Purpose: Proteins subjected to post-translational modifications, such as citrullination, carbamylation, acetylation, malondialdehyde (MDA) or malondialdehyde/acetaldehyde (MDA/MAA) modification are targeted by autoantibodies in seropositive rheumatoid arthritis…Abstract Number: 0608 • ACR Convergence 2022
Wnt Pathway Regulators R-spondin 3 and Dickkopf-related Protein 3 Demarcate a Transcriptional Gradient That Drives Synovial Fibroblast Inflammatory Pathology in Rheumatoid Arthritis
Background/Purpose: Synovial fibroblasts are key players in rheumatoid arthritis (RA) where they secrete inflammatory cytokines and directly instigate cartilage and bone destruction. However, most treatments…Abstract Number: 0626 • ACR Convergence 2022
Elucidating the Expression and Role of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Human Rheumatoid Arthritis Synovial Fibroblasts and a Rat Adjuvant-induced Arthritis Model
Background/Purpose: Proprotein convertase subtilisin/Kexin type-9 (PCSK9) is the most recognized serine protease for its pathological role in cardiovascular diseases, however, its role in inflammatory diseases,…Abstract Number: 0761 • ACR Convergence 2022
Identification of Outcome Domains in Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis and Polymyalgia Rheumatica: A Scoping Review by the OMERACT IrAE Working Group
Background/Purpose: Immune checkpoint inhibitors (ICI), increasingly used cancer therapeutics, can cause off-target inflammatory effects called immune-related adverse events (irAEs), including ICI-induced inflammatory arthritis (ICI-induced IA)…Abstract Number: 0848 • ACR Convergence 2022
Postoperative Flares and Peri-arthroscopic Management of Immunosuppressive Medications in Patients with Rheumatic Disease
Background/Purpose: To determine the rate and characteristics of postoperative flares in rheumatic disease patients undergoing arthroscopic surgery, and the role of perioperative immunosuppression (IS) management…Abstract Number: 0898 • ACR Convergence 2022
Risk of Aortic Stenosis and Undergoing Aortic Valve Replacement in Rheumatoid Arthritis: An Underrecognized Cardiovascular Complication
Background/Purpose: Valvular carditis is reported as a rare extra-articular manifestation of rheumatoid arthritis (RA). In animal models with coexistent inflammatory arthritis, pro-inflammatory infiltrates of T…Abstract Number: 0914 • ACR Convergence 2022
The Impact of Autoantibodies (RF and ACPA) on the Efficacy of Biological Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis: Meta-analysis of Randomized Controlled Trials
Background/Purpose: The impact of autoantibodies on the efficacy of bDMARDs in patients with rheumatoid arthritis (RA) is not yet clear. Despite the fact that this…Abstract Number: 0930 • ACR Convergence 2022
Delayed Response to Methotrexate Treatment in Rheumatoid Arthritis Patients Receiving Folic Acid Supplementation
Background/Purpose: MTX is the first line conventional synthetic DMARD (csDMARD) for the treatment of rheumatoid arthritis (RA), and folic acid (FA) supplementation is frequently co-prescribed…Abstract Number: 1122 • ACR Convergence 2022
Short Peripheral Blood Leukocyte Telomere Length in Rheumatoid Arthritis – Interstitial Lung Disease
Background/Purpose: Shortened telomere lengths (TL) have been associated with interstitial lung disease (ILD), in particular idiopathic pulmonary fibrosis (IPF). Given the phenotypic overlap between IPF…
- « Previous Page
- 1
- …
- 93
- 94
- 95
- 96
- 97
- …
- 188
- Next Page »